Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity

Inclusion Criteria: * Age ≥ 18 years. Histologically confirmed solid malignancy. Planned treatment with cisplatin starting from a dose of 60 mg/m2 per cycle (21-28 days each or fractionated). Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Baseline serum creatinine within normal range or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2. Ability to provide informed consent. Exclusion Criteria: * Pre existing renal impairment (eGFR \< 60〖" mL/min/1.73 m" 〗\^2or serum creatinine \> 1.5 × upper limit of normal). Concomitant use of known nephrotoxic drugs that cannot be stopped (e.g., aminoglycosides, amphotericin B, high dose NSAIDs). Uncontrolled hypertension, decompensated heart failure, or severe hepatic impairment. Known allergy or intolerance to ALA. Pregnancy or lactation. Participation in another interventional clinical trial.